Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

News
Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

In this episode of the Pharmaceutical Executive podcast, Bill Grambley, CEO of AllazoHealth, explores:

  • How AI can potentially revolutionize patient engagement and adherence
  • Utilizing patient-level data and predictive modeling
  • How AI can identify individual needs and preferences
  • The importance of ethical considerations and data privacy when leveraging AI in healthcare
  • and more!
Recent Videos
Arda Ural
Ted Sweetser
Ted Sweetser
Ted Sweetser
Amy Hessels, Bayer
Amy Hessels, Bayer
Related Content
Credit: Yurii Kibalnik | stock.adobe.com

FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis

Davy James
April 30th 2025
Article

AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

Pete Foley

$25B Potential in Accelerating AI’s Impact and Value in Pharma

Pete Foley
April 29th 2025
Article

Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Bill Coyle

Predicting and Planning for Tariff Impacts: Q&A with Bill Coyle

Mike Hollan
April 25th 2025
Article

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.

AbbVie Submits Biologics License Application to FDA for Novel Serotype E Botulinum Neurotoxin in Moderate to Severe Glabellar Lines

AbbVie Submits Biologics License Application to FDA for Novel Serotype E Botulinum Neurotoxin in Moderate to Severe Glabellar Lines

Don Tracy, Associate Editor
April 24th 2025
Article

The submission is backed by clinical data from over 2,100 patients, including two pivotal Phase III trials in patients treated with trenibotulinumtoxinE for moderate to severe glabellar lines.